UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5.

Authors:
Li J; Liang Y; Zhou S; Chen J; Wu C.

Journal:
Breast Cancer Res

Publication Year: 2024

DOI:
10.1186/s13058-024-01800-1

PMCID:
PMC10929172

PMID:
38468288

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Breast Cancer Res

Abbreviation: Breast Cancer Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive…
Nie J; Dang S; Zhu R and 2 more (2024) - Transparency Score: 3/6
Addition of polygenic risk score to a risk calculator for prediction of breast cancer in US Black w…
Zirpoli GR; Pfeiffer RM; Bertrand KA and 3 more (2024) - Transparency Score: 3/6
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable o…
Shatsky RA; Batra-Sharma H; Helsten T and 14 more (2024) - Transparency Score: 4/6
A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in ea…
López-Velazco JI; Manzano S; Otaño M and 8 more (2024) - Transparency Score: 3/6
Are better AI algorithms for breast cancer detection also better at predicting risk? A paired case-…
Santeramo R; Damiani C; Wei J and 2 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Competing interestsThe authors declare no competing interests. Ethical approvalThe animal study was carried out at Jinruijie Biotechnology Service Center in Chengdu, China, and received approval from the Ethics Committee of the Institution (Approval no. 2023056SPPH). Conflict of interestThe authors have no conflict of interest. Competing interests The authors declare no competing interests. Conflict of interest The authors have no conflict of interest."

Evidence found in paper:

"Funding This study was supported by Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, China. Grant no. 2023QN08."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025